Epigeneticists may be looking for epigenome-disease associations in the wrong place January 27, 2023Vol.49 No.04By Jacquelyn Cobb and Matthew Bin Han Ong
Conversation with The Cancer Letter Baylor’s Waterland & Coarfa: We see CoRSIVs as the new standard in epigenetic epidemiology January 27, 2023Vol.49 No.04By Jacquelyn Cobb and Matthew Bin Han Ong
Guest Editorial NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research January 27, 2023Vol.49 No.04By Lisa M. Coussens
FreeTrials & Tribulations Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization” January 27, 2023Vol.49 No.04By Mark J. Ratain and Garth W. Strohbehn
Cancer History ProjectConversation with The Cancer Letter Jim Allison believed in the power of T cells—when hardly anyone else did January 27, 2023Vol.49 No.04By Alexandria Carolan
FreeIn the Archives Duke marks 50 years of gynecologic care; celebrates legacies of oncology doctors and nurses January 27, 2023Vol.49 No.04
Guest Editorial ODAC Confidential: The seven deadly sins sponsors commit again and again at FDA presentations January 20, 2023Vol.49 No.03By Mikkael A. Sekeres
Conversation with The Cancer Letter City of Hope’s Mustafa Raoof: Medicare Advantage cancer patients more likely to die within 30 days after complex surgery January 20, 2023Vol.49 No.03By Matthew Bin Han Ong
FreeObituary C. David Allis, pioneer of chromatin biology and epigenetics, dies at 71 January 20, 2023Vol.49 No.03By Johnathan Whetstine
FreeIn the Archives The Cancer History Project highlights the contributions of Ahmedin Jemal and Isaac Craig Henderson January 20, 2023Vol.49 No.03
